Monte Rosa Therapeutics, Inc.
GLUE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -45% | -72.7% | 40% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 83.6% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | $0 | $0 |
| % Margin | -220.6% | -57.9% | 54.3% | 24.8% |
| Net Income | -$0 | -$0 | $0 | $0 |
| % Margin | -212.1% | -53% | 55.2% | 22.2% |
| EPS Diluted | -0.33 | -0.15 | 0.57 | 0.22 |
| % Growth | -120% | -126.3% | 159.1% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | $0 |